- Home
- BCRX vs DYN Comparison
BCRX vs DYN Comparison
Compare BCRX & DYN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BCRX
- DYN
- Stock Information
- Founded
- BCRX 1986
- DYN 1984
- Country
- BCRX United States
- DYN United States
- Employees
- BCRX N/A
- DYN N/A
- Industry
- BCRX Biotechnology: Biological Products (No Diagnostic Substances)
- DYN Medicinal Chemicals and Botanical Products
- Sector
- BCRX Health Care
- DYN Health Care
- Exchange
- BCRX Nasdaq
- DYN Nasdaq
- Market Cap
- BCRX 1.7B
- DYN 1.4B
- IPO Year
- BCRX 1994
- DYN 2020
- Fundamental
- Price
- BCRX $9.19
- DYN $9.67
- Analyst Decision
- BCRX Buy
- DYN Strong Buy
- Analyst Count
- BCRX 9
- DYN 15
- Target Price
- BCRX $16.89
- DYN $43.60
- AVG Volume (30 Days)
- BCRX 3.6M
- DYN 2.8M
- Earning Date
- BCRX 08-04-2025
- DYN 08-11-2025
- Dividend Yield
- BCRX N/A
- DYN N/A
- EPS Growth
- BCRX N/A
- DYN N/A
- EPS
- BCRX N/A
- DYN N/A
- Revenue
- BCRX $503,485,000.00
- DYN N/A
- Revenue This Year
- BCRX $39.04
- DYN N/A
- Revenue Next Year
- BCRX $13.26
- DYN N/A
- P/E Ratio
- BCRX N/A
- DYN N/A
- Revenue Growth
- BCRX 41.67
- DYN N/A
- 52 Week Low
- BCRX $6.02
- DYN $6.36
- 52 Week High
- BCRX $11.31
- DYN $47.45
- Technical
- Relative Strength Index (RSI)
- BCRX 34.12
- DYN 32.17
- Support Level
- BCRX $9.19
- DYN $10.00
- Resistance Level
- BCRX $10.07
- DYN $10.74
- Average True Range (ATR)
- BCRX 0.34
- DYN 0.88
- MACD
- BCRX -0.18
- DYN -0.48
- Stochastic Oscillator
- BCRX 8.10
- DYN 0.53
About BCRX BioCryst Pharmaceuticals Inc.
BioCryst Pharmaceuticals Inc is a biotechnology company involved mainly in the research and development of novel small-molecule drugs, to block key enzymes involved in infectious and inflammatory diseases. Biocryst's research is based on multiple scientific disciplines like biology, computer modeling, and medicinal chemistry. Its products and candidates target the following therapeutic areas: acute uncomplicated influenza; uncomplicated seasonal influenza; hereditary angioedema; filoviruses, including the Ebola and Marburg viruses; and oncology.
About DYN Dyne Therapeutics Inc.
Dyne Therapeutics Inc is a clinical-stage neuromuscular disease company focused on discovering and advancing life-transforming therapeutics for people living with genetically driven neuromuscular diseases. Its FORCE platform develops targeted therapeutics that are designed to overcome limitations in delivery to muscle tissue and the central nervous system, or CNS. Its FORCE platform therapeutics consist of a payload that is rationally designed to target the genetic basis of the disease are seeking to treat, a linker, and an antigen-binding fragment, that attaches to the payload using the linker. Its Pipeline includes DYNE-101, DYNE-251, DYNE-302, and DYNE-401.